Therapeutic strategies of Alzheimer's disease through manipulation of Aβ metabolism: A focus on Aβ-degrading peptidase, neprilysin

Drug Development Research

Volumn 56, Issue 2, 2002, Pages 171-183

  Fukami, Shinjiro ^a,b   Iwata, Nobuhisa ^a   Saido, Takaomi C ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amyloid peptide; Catabolism; Neprilysin

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BETA SECRETASE; COPPER COMPLEX; GAMMA SECRETASE; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE METALLOENDOPEPTIDASE; METAL CHELATE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDASE; ZINC COMPLEX;

ALZHEIMER DISEASE; CATABOLISM; DRUG POTENCY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; STEADY STATE; VACCINATION;

EID: 0036597135     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10073     Document Type: Review

References (99)

1. Notch signaling: Cell fate control and signal integration in development
2. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis
3. Characterization of copper interactions with Alzheimer amyloid β peptides: Identification of an attomolar-affinity copper binding site on amyloid β1-42
4. Histochemical visualization of neutral endopeptidase-24.11 (enkephalinase) activity in rat brain: Cellular localization and codistribution with enkephalins in the globus pallidus
5. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1-40)
6. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
7. Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase A (angiotensin converting enzyme) in the pig brain: A study using subcellular fractionation and electron microscopic immunocytochemistry
8. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo
9. Neuropathological staging of Alzheimer-related changes
10. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q
11. The amyloid β-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily
12. Rapid induction of Alzheimer Aβ amyloid formation by zinc
13. Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor
14. Presenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch
15. A new brain metalloendopeptidase which degrades the Alzheimer β-amyloid 1-40 peptide producing soluble fragments without neurotoxic effects
16. Nerve inflammation halts trial for Alzheimer's drug
17. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
18. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure
19. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-mnyloid accumulation in Alzheimer's disease transgenic mice
20. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695
21. Selective loss of central cholinergic neurons in Alzheimer's disease
22. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
23. Amino acid sequence of rabbit kidney neutral endopeptidase 24.11 (enkephalinase) deduced from a complementary DNA
24. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
25. Degradation of the Alzheimer's amyloid β peptide by endothelin-converting enzyme
26. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
27. Interneurons of the hippocampus
28. Aβ-degrading endopeptidase, neprilysin, in mouse brain: Synaptic and axonal localization inversely correlating with Aβ pathology
29. Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease
30. Clearance of extracellular and cell-associated amyloid β peptide through viral expression of neprilysin in primary neurons
31. Cathepsin D is involved in the clearance of Alzheimer's β-amyloid protein
32. Amyloid, the presenilins and Alzheimer's disease
33. Alzheimer's disease. In search of γ-secretase
34. Neutral endopeptidase can hydrolyze β-amyloid(1-40) but shows no effect on β-amyloid precursor protein metabolism
35. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity
36. Zinc-induced Alzheimer's Aβ1-40 aggregation is mediated by conformational factors
37. Nonsteroidal antiinflaminatory drugs and the risk of Alzheimer's disease
38. Region-specific reduction of Aβ-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging
39. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
40. Metabolic regulation of brain Aβ by neprilysin
41. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
42. Statins and the risk of dementia
43. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I
44. Kinesin-mediated axonal transport of a membrane compartment containing β-secretase and presenilin-1 requires APP
45. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase
46. Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease
47. Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4
48. Tissue-specific expression of rat neutral endopeptidase (neprilysin) mRNAs
49. Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state
50. Proprotein convertase activity contributes to the processing of the Alzheimer's β-amyloid precursor protein in human cells: Evidence for a role of the prohormone convertase PC7 in the constitutive α-secretase pathway
51. Copper, iron and zinc in Alzheimer's disease senile plaques
52. Neutral endopeptidase modulation of septic shock
53. The control of microvascular permeability and blood pressure by neutral endopeptidase
54. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation
55. GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease revisited
56. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
57. Progressive brain dysfunction following intracerebroventricular infusion of β (1-42)-amyloid peptide
58. Accumulation of murine amyloidβ42 in a gene-dosage-dependent manner in PS1 'knock-in' mice
59. Effects of PS1 deficiency on membrane protein trafficking in neurons
60. Regulation of APP cleavage by α-, β- and γ-secretases
61. Vulnerability of small GABAergic neurons to human β-amyloid pentapeptide
62. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals
63. Current concepts in mild cognitive impairment
64. New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch cleavage
65. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice
66. Detailed immunoautoradiographic mapping of enkephalinase (EC 3.4.24.11) in rat central nervous system: Comparison with enkephalins and substance P
67. Alzheimer's disease: The value of transgenic and gene targeted models
68. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation
69. Clinical trial of indomethacin in Alzheimer's disease
70. Alzheimer's disease as proteolytic disorders: Anabolism and catabolism of β-amyloid
71. Opioid-related changes in nociceptive threshold and in tissue levels of enkephalins after target disruption of the gene for neutral endopeptidase (EC 3.4.24.11) in mice
72. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
73. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
74. Somatostatin receptors in the central nervous system
75. Translating cell biology into therapeutic advances in Alzheimer's disease
76. Alzheimer's disease: Genes, proteins, and therapy
77. Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide
78. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
79. Neprilysin degrades both amyloid β peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases
80. Tau, β-amyloid and β-amyloid precursor protein distribution in the entorhinal-hippocampal alvear and perforant pathways in the Alzheimer's brain
81. Functional rafts in cell membranes
82. Topographic organization of the projections from the entorhinal area to the hippocampal formation of the rat
83. Risk of Alzheimer's disease and duration of NSAID use
84. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains
85. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid β peptide in the brain
86. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function
87. Plasmin cleavage of the amyloid β-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity
88. β cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
89. Neuronal localization of the neutral endopeptidase 'enkephalinase' in rat brain revealed by lesions and autoradiography
90. Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain
91. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
92. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
93. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
94. TGF-β1 promotes microglial amyloid- β clearance and reduces plaque burden in transgenic mice
95. Selective localization of gelatinase A, an enzyme degrading β-amyloid protein, in white matter microglia and in Schwann cells
96. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
97. Reduced neprilysin in high plaque areas of Alzheimer brain: A possible relationship to deficient degradation of β-amyloid peptide
98. Relationship between β amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain